Prevalence and impact of diabetes mellitus in hospitalized COVID-19 patients in a Tunisian Center: a cross-sectional study.
COVID-19
SARS-CoV-2
Tunisia
complications
death
diabetes mellitus
intensive care units
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
15
05
2023
accepted:
15
07
2023
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
The outbreak of the coronavirus disease 2019 (COVID-19) has become an evolving worldwide health crisis. With the rising prevalence of diabetes mellitus has come an increasing awareness of their impacts on infectious diseases, and the risk for postinfection complications and mortality from critical infections. The objective of this study was to evaluate the prevalence and impact of diabetes mellitus on the severity and mortality of COVID-19. Data of laboratory-confirmed hospitalized patients at the COVID-19 unit between September 2020 and August 2021 were analyzed, in a cross-sectional study. The population was classified into two groups: COVID-19 patients with and without diabetes. Primary outcomes were the overall length of hospital stay, the admission to the ICU, and death. The association between diabetes and death was assessed in a Cox proportional hazards model. A total of 866 patients were included. There were 270 (31.2%) patients with diabetes. Diabetic patients were more likely to have hypertension (58.1 vs. 33.4%), cardiovascular disease (18.5 vs. 10.4%), and dyslipidaemia (17.8 vs. 7.2). Overall, 263 patients died, among them only 86 in the diabetic group ( Diabetes was associated with a greater risk of complications in patients with COVID-19. Special attention to diabetic patients during treatment must be given to avoid these complications.
Sections du résumé
Background
UNASSIGNED
The outbreak of the coronavirus disease 2019 (COVID-19) has become an evolving worldwide health crisis. With the rising prevalence of diabetes mellitus has come an increasing awareness of their impacts on infectious diseases, and the risk for postinfection complications and mortality from critical infections.
Objective
UNASSIGNED
The objective of this study was to evaluate the prevalence and impact of diabetes mellitus on the severity and mortality of COVID-19.
Methods
UNASSIGNED
Data of laboratory-confirmed hospitalized patients at the COVID-19 unit between September 2020 and August 2021 were analyzed, in a cross-sectional study. The population was classified into two groups: COVID-19 patients with and without diabetes. Primary outcomes were the overall length of hospital stay, the admission to the ICU, and death. The association between diabetes and death was assessed in a Cox proportional hazards model.
Results
UNASSIGNED
A total of 866 patients were included. There were 270 (31.2%) patients with diabetes. Diabetic patients were more likely to have hypertension (58.1 vs. 33.4%), cardiovascular disease (18.5 vs. 10.4%), and dyslipidaemia (17.8 vs. 7.2). Overall, 263 patients died, among them only 86 in the diabetic group (
Conclusion
UNASSIGNED
Diabetes was associated with a greater risk of complications in patients with COVID-19. Special attention to diabetic patients during treatment must be given to avoid these complications.
Identifiants
pubmed: 37663697
doi: 10.1097/MS9.0000000000001110
pii: AMSU-D-23-01075
pmc: PMC10473318
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4315-4320Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare that they have no financial conflicts of interest with regard to the content of this report.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
N Engl J Med. 2015 Oct 29;373(18):1720-32
pubmed: 26510021
J Prev Med Hyg. 2023 May 16;64(1):E3-E8
pubmed: 37293451
Diabet Med. 2006 Jun;23(6):623-8
pubmed: 16759303
Aging (Albany NY). 2020 Apr 8;12(7):6049-6057
pubmed: 32267833
Diabetes Care. 2003 Jan;26 Suppl 1:S5-20
pubmed: 12502614
Diabetes Obes Metab. 2020 Oct;22(10):1907-1914
pubmed: 32496012
Wien Klin Wochenschr. 2020 Jul;132(13-14):356-361
pubmed: 32435867
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):535-545
pubmed: 32408118
China CDC Wkly. 2020 May 8;2(19):321-326
pubmed: 34594648
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
Diabetes Metab Res Rev. 2021 Mar;37(3):e3388
pubmed: 32683744
Diabetes Metab Syndr. 2011 Oct-Dec;5(4):222-7
pubmed: 25572769
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Leukoc Biol. 2018 Sep;104(3):525-534
pubmed: 30066958
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
Gastroenterol Nurs. 2021 Jan-Feb 01;44(1):E1-E10
pubmed: 33538525
Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-792
pubmed: 32687793
Int J Surg. 2021 Dec;96:106165
pubmed: 34774726
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Am J Physiol Renal Physiol. 2018 Aug 1;315(2):F263-F274
pubmed: 29561187